Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Orthocell Ltd ( (AU:OCC) ) is now available.
Orthocell Ltd has appointed MontsMed as the exclusive distributor for its Remplir product in Hong Kong, marking a significant step in its Asian commercialization strategy. This move is expected to facilitate market access in the Guangdong-Hong Kong-Macao Greater Bay Area, a region with a population of around 100 million, and complements ongoing sales efforts in Singapore and anticipated market entry in Thailand. The company’s strategic expansion is supported by a robust financial position and the recent appointment of a Commercial Director to oversee operations in Asia.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Ltd is a regenerative medicine company focused on developing and commercializing medical devices for nerve repair. Their primary product, Remplir, is a collagen wrap used in nerve repair surgery to enhance the repair and regeneration of damaged nerves. The company targets the global nerve repair market, valued at over US$3.5 billion, and is expanding its presence in Asia, Australia, and New Zealand.
Average Trading Volume: 661,897
Technical Sentiment Signal: Buy
Current Market Cap: A$339.9M
For a thorough assessment of OCC stock, go to TipRanks’ Stock Analysis page.